Bart De Valk

Hoofddorp, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.

Journal: British journal of haematology

Published: August 06, 2025

First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.

First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.

Journal: JAMA oncology

Published: November 21, 2024

70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study.

70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study.

Journal: Breast cancer research and treatment

Published: June 06, 2024

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.

Journal: The Lancet. Oncology

Published: January 26, 2023

Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study.

Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study.

Journal: Leukemia & lymphoma

Published: June 13, 2020

PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.

PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.

Journal: Journal of cancer research and clinical oncology

Published: May 21, 2020

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.

Journal: Breast cancer research and treatment

Published: March 09, 2017

Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.

Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 10, 2014

Showing 1-8 of 8

Last Updated: 09/26/2026